Has Kanwaljit Brar received payments from drug or device companies?

Yes. Drug and device makers reported $8,956 in general payments to Kanwaljit Brar across 58 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kanwaljit Brar did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kanwaljit Brar come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kanwaljit Brar

Pediatrics · New York, NYNPI 1306005723

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (58.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Incyte Corporation accounts for 80.2% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2022 at $7,413 and has fallen 94.8% since, to $387 in 2025. Among pediatrics clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,956in general payments, 2019–2025

Across 58 payments — averaging $154.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Incyte Corporation$7K
Sanofi$546
Kaleo, Inc.$361
Aimmune Therapeutics, Inc.$350
ARS Pharmaceuticals Operations, Inc.$142
AstraZeneca$125
plus $247 from 4 others

$245,614in research payments, 2019–2025

Across 59 payments — averaging $4162.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Incyte Corporation$203K
Sanofi$43K

What the payments were for

Consulting fees$5,22758%
Speaking & faculty fees$6798%
Travel & lodging$1,26214%
Food & beverage$1,69219%
Education$951%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Incyte Corporation	14	$7,185
Sanofi	12	$546
Kaleo, Inc.	16	$361
Aimmune Therapeutics, Inc.	1	$350
ARS Pharmaceuticals Operations, Inc.	7	$142
AstraZeneca	1	$125
Sanofi-aventis U.S. LLC	1	$95
GSK	4	$71
Grifols USA, LLC	1	$49
Biocryst US Sales Co., LLC	1	$31

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,956 in reported general payments places this provider in the 95th percentile of 4,055 pediatrics providers in New York.

See all pediatrics providers in New York →

Other pediatrics in New York

Kathryn FitzgeraldNew York$80K
Rudolph LeibelNew York$67K
Shakeel ModakNew York$64K
Jean-Laurent CasanovaNew York$62K
Randall KayeNew York$46K
Kevin CurranNew York$35K
Hsiang YinNew York$25K
Jennifer TrachtenbergNew York$23K
John LantosNew York$12K
Stephanie ChristensenNew York$11K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →